P&T
Our
Other
Journal
MediMedia Managed Markets
Managed Care

 

Comparison of Human Growth Hormone Products' Cost in Pediatric and Adult Patients

MANAGED CARE September 2007. © MediMedia USA
Peer-Reviewed

Comparison of Human Growth Hormone Products' Cost in Pediatric and Adult Patients

Payers' drug costs for human growth hormone are related to product waste that is related to the container in which the product is supplied
Gary R. Bazalo, MS
Managed Solutions, Conifer, Colo.
Ashish V. Joshi, PhD
Novo Nordisk, Princeton, N.J.
John Germak, MD
Novo Nordisk, Princeton, N.J.

A Budgetary Impact Model

Payers' drug costs for human growth hormone are related to product waste that is related to the container in which the product is supplied

Gary R. Bazalo, MS

Managed Solutions, Conifer, Colo.

Ashish V. Joshi, PhD

Novo Nordisk, Princeton, N.J.

John Germak, MD

Novo Nordisk, Princeton, N.J.

Abstract

We assessed the economic impact to the United States payer of recombinant human growth hormone (rhGH) utilization, comparing the relative dosage efficiency of marketed pen-based and vial-based products in a pediatric and in an adult population. A budgetary impact model calculated drug costs based on product waste and cost. Waste was the difference between prescribed dose, based on patient weight, and actual delivered dose, based on dosing increments and maximum deliverable dose for pens and a fixed-percent waste as derived from the literature for vials.

Annual wholesale acquisition costs were calculated based upon total milligrams delivered, using a daily dose of 0.03 mg/kg for pediatric patients and 0.016 mg/kg for adults. Total annual drug costs were compared for two scenarios: 1) a product mix based on national market share and 2) restricting use to the product with lowest waste.

Based on the literature, waste for each vial product was 23 percent. Among individual pens, waste was highest for Humatrope 24 mg (19.5 percent pediatric, 14.3 percent adult) and lowest for Norditropin NordiFlex 5 mg (1.1 percent pediatric, 1 percent adult). Restricting use to the brand with least waste (Norditropin), compared to national product share mix, resulted in a 10.2 percent reduction in annual pediatric patient cost from $19,026 to $17,089 and an 8 percent reduction in annual adult patient cost from $24,099 to $22,161.

We concluded that pen delivery systems result in less waste than vial and syringe. Considering all approved delivery systems, Norditropin resulted in the least product waste and lower annual patient cost for both pediatric and adult populations.

Corresponding author:
Gary R. Bazalo, MS
Managed Solutions
28154 Belle Meade Drive
Conifer, Colo. 80433

Gary R. Bazalo, MS, discloses that he is a consultant to Novo Nordisk.
Ashish V. Joshi, PhD, and John Germak, MD, disclose that they are employees of Novo Nordisk.

Meetings

Pharmaceutical Pricing and Contracting Conference Philadelphia, PA September 22–23, 2014
Private Health Insurance Exchanges Conference Washington, D.C. October 7–8, 2014
National Healthcare Facility Management Summit Palm Beach, FL October 16–17, 2014
National Healthcare CFO Summit Las Vegas, NV October 19–21, 2014
National Healthcare CXO Summit Las Vegas, NV October 19–21, 2014
Innovative Member Engagement Operations For Health Plans Las Vegas, NV October 20–21, 2014
4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014